{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:43:13Z","timestamp":1785544993314,"version":"3.56.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T00:00:00Z","timestamp":1716854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T00:00:00Z","timestamp":1716854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203080"],"award-info":[{"award-number":["82203080"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203081"],"award-info":[{"award-number":["82203081"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Glioblastoma (GBM) is the most aggressive and lethal brain tumor in adults. This study aimed to investigate the functional significance of aryl hydrocarbon receptor nuclear translocator (ARNT) in the pathogenesis of GBM. Analysis of public datasets revealed ARNT is upregulated in GBM tissues compared to lower grade gliomas or normal brain tissues. Higher ARNT expression correlated with the mesenchymal subtype and poorer survival in GBM patients. Silencing ARNT using lentiviral shRNAs attenuated the proliferative, invasive, and stem-like capabilities of GBM cell lines, while ARNT overexpression enhanced these malignant phenotypes. Single-cell RNA sequencing uncovered that ARNT is highly expressed in a stem-like subpopulation and is involved in regulating glycolysis, hypoxia response, and stress pathways. Mechanistic studies found ARNT activates p38 mitogen-activated protein kinase (MAPK) signaling to promote chemoresistance in GBM cells. Disrupting the ARNT\/p38\u03b1 protein interaction via the ARNT PAS-A domain restored temozolomide sensitivity. Overall, this study demonstrates ARNT functions as an oncogenic driver in GBM pathogenesis and represents a promising therapeutic target.<\/jats:p>","DOI":"10.1038\/s41419-024-06735-1","type":"journal-article","created":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T15:01:45Z","timestamp":1716908505000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Targeting ARNT attenuates chemoresistance through destabilizing p38\u03b1-MAPK signaling in glioblastoma"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4791-1966","authenticated-orcid":false,"given":"Wahafu","family":"Alafate","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gen","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiantao","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiping","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shichao","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,28]]},"reference":[{"key":"6735_CR1","first-page":"26","volume":"9","author":"QL Guo","year":"2022","unstructured":"Guo QL, Dai XL, Yin MY, Cheng HW, Qian HS, Wang H, et al. Nanosensitizers for sonodynamic therapy for glioblastoma multiforme: current progress and future perspectives. Mil Med Res. 2022;9:26.","journal-title":"Mil Med Res"},{"key":"6735_CR2","doi-asserted-by":"publisher","first-page":"12608","DOI":"10.3390\/ijms222212608","volume":"22","author":"M Domenech","year":"2021","unstructured":"Domenech M, Hernandez A, Plaja A, Martinez-Balibrea E, Balana C. Hypoxia: the cornerstone of glioblastoma. Int J Mol Sci. 2021;22:12608.","journal-title":"Int J Mol Sci"},{"key":"6735_CR3","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.semcancer.2022.06.007","volume":"86","author":"I Khan","year":"2022","unstructured":"Khan I, Baig MH, Mahfooz S, Imran MA, Khan MI, Dong JJ, et al. Nanomedicine for glioblastoma: progress and future prospects. Semin Cancer Biol. 2022;86:172\u201386.","journal-title":"Semin Cancer Biol"},{"key":"6735_CR4","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s13046-020-01750-4","volume":"39","author":"W Alafate","year":"2020","unstructured":"Alafate W, Xu D, Wu W, Xiang J, Ma X, Xie W, et al. Loss of PLK2 induces acquired resistance to temozolomide in GBM via activation of notch signaling. J Exp Clin Cancer Res. 2020;39:239.","journal-title":"J Exp Clin Cancer Res"},{"key":"6735_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01189-3","volume":"19","author":"J Cheng","year":"2020","unstructured":"Cheng J, Meng J, Zhu L, Peng Y. Exosomal noncoding RNAs in Glioma: biological functions and potential clinical applications. Mol Cancer. 2020;19:66.","journal-title":"Mol Cancer"},{"key":"6735_CR6","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1007\/s11427-017-9178-y","volume":"60","author":"Y Huang","year":"2017","unstructured":"Huang Y, Lin D, Taniguchi CM. Hypoxia inducible factor (HIF) in the tumor microenvironment: friend or foe? Sci China Life Sci. 2017;60:1114\u201324.","journal-title":"Sci China Life Sci"},{"key":"6735_CR7","doi-asserted-by":"publisher","first-page":"20130676","DOI":"10.1259\/bjr.20130676","volume":"87","author":"SR McKeown","year":"2014","unstructured":"McKeown SR. Defining normoxia, physoxia and hypoxia in tumours-implications for treatment response. Br J Radiol. 2014;87:20130676.","journal-title":"Br J Radiol"},{"key":"6735_CR8","doi-asserted-by":"publisher","first-page":"215","DOI":"10.2119\/molmed.2014.00032","volume":"20","author":"M Mandl","year":"2014","unstructured":"Mandl M, Depping R. Hypoxia-inducible aryl hydrocarbon receptor nuclear translocator (ARNT) (HIF-1beta): is it a rare exception? Mol Med. 2014;20:215\u201320.","journal-title":"Mol Med"},{"key":"6735_CR9","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/mc.20585","volume":"49","author":"S Shi","year":"2010","unstructured":"Shi S, Yoon DY, Hodge-Bell K, Huerta-Yepez S, Hankinson O. Aryl hydrocarbon nuclear translocator (hypoxia inducible factor 1beta) activity is required more during early than late tumor growth. Mol Carcinog. 2010;49:157\u201365.","journal-title":"Mol Carcinog"},{"key":"6735_CR10","first-page":"56","volume":"20","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Han F, Zhang X, Zhou C, Huang D. Aryl hydrocarbon receptor nuclear translocator promotes the proliferation and invasion of clear cell renal cell carcinoma cells potentially by affecting the glycolytic pathway. Oncol Lett. 2020;20:56.","journal-title":"Oncol Lett"},{"key":"6735_CR11","doi-asserted-by":"publisher","first-page":"10710","DOI":"10.18632\/oncotarget.7539","volume":"7","author":"KA Gardella","year":"2016","unstructured":"Gardella KA, Muro I, Fang G, Sarkar K, Mendez O, Wright CW. Aryl hydrocarbon receptor nuclear translocator (ARNT) isoforms control lymphoid cancer cell proliferation through differentially regulating tumor suppressor p53 activity. Oncotarget. 2016;7:10710\u201322.","journal-title":"Oncotarget"},{"key":"6735_CR12","doi-asserted-by":"publisher","first-page":"3899","DOI":"10.1002\/cam4.1596","volume":"7","author":"C Wu","year":"2018","unstructured":"Wu C, Yang T, Liu Y, Lu Y, Yang Y, Liu X, et al. ARNT\/HIF-1beta links high-risk 1q21 gain and microenvironmental hypoxia to drug resistance and poor prognosis in multiple myeloma. Cancer Med. 2018;7:3899\u2013911.","journal-title":"Cancer Med"},{"key":"6735_CR13","first-page":"818","volume":"7","author":"C Qin","year":"2001","unstructured":"Qin C, Wilson C, Blancher C, Taylor M, Safe S, Harris AL. Association of ARNT splice variants with estrogen receptor-negative breast cancer, poor induction of vascular endothelial growth factor under hypoxia, and poor prognosis. Clin Cancer Res. 2001;7:818\u201323.","journal-title":"Clin Cancer Res"},{"key":"6735_CR14","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1124\/mol.111.077305","volume":"81","author":"DP Dever","year":"2012","unstructured":"Dever DP, Opanashuk LA. The aryl hydrocarbon receptor contributes to the proliferation of human medulloblastoma cells. Mol Pharmacol. 2012;81:669\u201378.","journal-title":"Mol Pharmacol"},{"key":"6735_CR15","doi-asserted-by":"publisher","first-page":"e99242","DOI":"10.1371\/journal.pone.0099242","volume":"9","author":"JM Shieh","year":"2014","unstructured":"Shieh JM, Shen CJ, Chang WC, Cheng HC, Chan YY, Huang WC, et al. An increase in reactive oxygen species by deregulation of ARNT enhances chemotherapeutic drug-induced cancer cell death. PLoS ONE. 2014;9:e99242.","journal-title":"PLoS ONE"},{"key":"6735_CR16","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s12149-019-01341-0","volume":"33","author":"M Hirata","year":"2019","unstructured":"Hirata M, Yao T, Fujimura S, Kanai Y, Yoshimoto M, Sato T, et al. Development of a p38alpha-selective radioactive probe for qualitative diagnosis of cancer using SPECT. Ann Nucl Med. 2019;33:333\u201343.","journal-title":"Ann Nucl Med"},{"key":"6735_CR17","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1016\/S0960-894X(98)00589-7","volume":"8","author":"JR Henry","year":"1998","unstructured":"Henry JR, Rupert KC, Dodd JH, Turchi IJ, Wadsworth SA, Cavender DE, et al. Potent inhibitors of the MAP kinase p38. Bioorg Med Chem Lett. 1998;8:3335\u201340.","journal-title":"Bioorg Med Chem Lett"},{"key":"6735_CR18","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1158\/0008-5472.CAN-15-0173","volume":"75","author":"A Igea","year":"2015","unstructured":"Igea A, Nebreda AR. The stress kinase p38alpha as a target for cancer therapy. Cancer Res. 2015;75:3997\u20134002.","journal-title":"Cancer Res"},{"key":"6735_CR19","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1042\/BJ20100323","volume":"429","author":"A Cuadrado","year":"2010","unstructured":"Cuadrado A, Nebreda AR. Mechanisms and functions of p38 MAPK signalling. Biochem J. 2010;429:403\u201317.","journal-title":"Biochem J"},{"key":"6735_CR20","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nrc2694","volume":"9","author":"EF Wagner","year":"2009","unstructured":"Wagner EF, Nebreda AR. Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer. 2009;9:537\u201349.","journal-title":"Nat Rev Cancer"},{"key":"6735_CR21","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1177\/1947601913507951","volume":"4","author":"HK Koul","year":"2013","unstructured":"Koul HK, Pal M, Koul S. Role of p38 MAP kinase signal transduction in solid tumors. Genes Cancer. 2013;4:342\u201359.","journal-title":"Genes Cancer"},{"key":"6735_CR22","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.molmed.2009.06.005","volume":"15","author":"LR Coulthard","year":"2009","unstructured":"Coulthard LR, White DE, Jones DL, McDermott MF, Burchill SA. p38(MAPK): stress responses from molecular mechanisms to therapeutics. Trends Mol Med. 2009;15:369\u201379.","journal-title":"Trends Mol Med"},{"key":"6735_CR23","doi-asserted-by":"publisher","first-page":"38973","DOI":"10.1074\/jbc.M002856200","volume":"275","author":"G Chen","year":"2000","unstructured":"Chen G, Hitomi M, Han J, Stacey DW. The p38 pathway provides negative feedback for Ras proliferative signaling. J Biol Chem. 2000;275:38973\u201380.","journal-title":"J Biol Chem"},{"key":"6735_CR24","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1165\/ajrcmb.26.5.4689","volume":"26","author":"AK Greenberg","year":"2002","unstructured":"Greenberg AK, Basu S, Hu J, Yie TA, Tchou-Wong KM, Rom WN, et al. Selective p38 activation in human non-small cell lung cancer. Am J Respir Cell Mol Biol. 2002;26:558\u201364.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"6735_CR25","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1002\/cncr.11940","volume":"100","author":"FJ Esteva","year":"2004","unstructured":"Esteva FJ, Sahin AA, Smith TL, Yang Y, Pusztai L, Nahta R, et al. Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma. Cancer. 2004;100:499\u2013506.","journal-title":"Cancer"},{"key":"6735_CR26","doi-asserted-by":"publisher","first-page":"5267","DOI":"10.1038\/sj.onc.1210332","volume":"26","author":"MR Junttila","year":"2007","unstructured":"Junttila MR, Ala-Aho R, Jokilehto T, Peltonen J, Kallajoki M, Grenman R, et al. p38alpha and p38delta mitogen-activated protein kinase isoforms regulate invasion and growth of head and neck squamous carcinoma cells. Oncogene. 2007;26:5267\u201379.","journal-title":"Oncogene"},{"key":"6735_CR27","doi-asserted-by":"publisher","first-page":"16483","DOI":"10.1074\/jbc.270.28.16483","volume":"270","author":"M Karin","year":"1995","unstructured":"Karin M. The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem. 1995;270:16483\u20136.","journal-title":"J Biol Chem"},{"key":"6735_CR28","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1002\/path.1975","volume":"209","author":"M Pomerance","year":"2006","unstructured":"Pomerance M, Quillard J, Chantoux F, Young J, Blondeau JP. High-level expression, activation, and subcellular localization of p38-MAP kinase in thyroid neoplasms. J Pathol. 2006;209:298\u2013306.","journal-title":"J Pathol"},{"key":"6735_CR29","doi-asserted-by":"publisher","first-page":"10528","DOI":"10.1073\/pnas.0504367102","volume":"102","author":"CF Gao","year":"2005","unstructured":"Gao CF, Xie Q, Su YL, Koeman J, Khoo SK, Gustafson M, et al. Proliferation and invasion: plasticity in tumor cells. Proc Natl Acad Sci USA. 2005;102:10528\u201333.","journal-title":"Proc Natl Acad Sci USA"},{"key":"6735_CR30","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1002\/jnr.23687","volume":"94","author":"V Pandey","year":"2016","unstructured":"Pandey V, Bhaskara VK, Babu PP. Implications of mitogen-activated protein kinase signaling in glioma. J Neurosci Res. 2016;94:114\u201327.","journal-title":"J Neurosci Res"},{"key":"6735_CR31","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.7150\/thno.9150","volume":"6","author":"M Cheray","year":"2016","unstructured":"Cheray M, Pacaud R, Nadaradjane A, Oliver L, Vallette FM, Cartron PF. Specific inhibition of DNMT3A\/ISGF3gamma interaction increases the temozolomide efficiency to reduce tumor growth. Theranostics. 2016;6:1988\u201399.","journal-title":"Theranostics"},{"key":"6735_CR32","doi-asserted-by":"publisher","first-page":"5497","DOI":"10.7150\/thno.33800","volume":"9","author":"W Huang","year":"2019","unstructured":"Huang W, Zhong Z, Luo C, Xiao Y, Li L, Zhang X, et al. The miR-26a\/AP-2alpha\/Nanog signaling axis mediates stem cell self-renewal and temozolomide resistance in glioma. Theranostics. 2019;9:5497\u2013516.","journal-title":"Theranostics"},{"key":"6735_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/sdata.2017.24","volume":"4","author":"Z Zhao","year":"2017","unstructured":"Zhao Z, Meng F, Wang W, Wang Z, Zhang C, Jiang T. Comprehensive RNA-seq transcriptomic profiling in the malignant progression of gliomas. Sci Data. 2017;4:170024.","journal-title":"Sci Data"},{"key":"6735_CR34","doi-asserted-by":"publisher","first-page":"9065","DOI":"10.1158\/0008-5472.CAN-09-2307","volume":"69","author":"LA Gravendeel","year":"2009","unstructured":"Gravendeel LA, Kouwenhoven MC, Gevaert O, de Rooi JJ, Stubbs AP, Duijm JE, et al. Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology. Cancer Res. 2009;69:9065\u201372.","journal-title":"Cancer Res"},{"key":"6735_CR35","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1158\/1541-7786.MCR-08-0435","volume":"7","author":"S Madhavan","year":"2009","unstructured":"Madhavan S, Zenklusen JC, Kotliarov Y, Sahni H, Fine HA, Buetow K. Rembrandt: helping personalized medicine become a reality through integrative translational research. Mol Cancer Res. 2009;7:157\u201367.","journal-title":"Mol Cancer Res"},{"key":"6735_CR36","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.cell.2015.12.028","volume":"164","author":"M Ceccarelli","year":"2016","unstructured":"Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA, et al. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell. 2016;164:550\u201363.","journal-title":"Cell"},{"key":"6735_CR37","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43:e47.","journal-title":"Nucleic Acids Res"},{"key":"6735_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04512-6","volume":"13","author":"J Xiang","year":"2022","unstructured":"Xiang J, Alafate W, Wu W, Wang Y, Li X, Xie W, et al. NEK2 enhances malignancies of glioblastoma via NIK\/NF-kappaB pathway. Cell Death Dis. 2022;13:58.","journal-title":"Cell Death Dis"},{"key":"6735_CR39","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s40478-021-01151-4","volume":"9","author":"Y Kim","year":"2021","unstructured":"Kim Y, Varn FS, Park SH, Yoon BW, Park HR, Lee C, et al. Perspective of mesenchymal transformation in glioblastoma. Acta Neuropathol Commun. 2021;9:50.","journal-title":"Acta Neuropathol Commun"},{"key":"6735_CR40","doi-asserted-by":"publisher","first-page":"msac177","DOI":"10.1093\/molbev\/msac177","volume":"39","author":"Y Chander","year":"2022","unstructured":"Chander Y, Kumar R, Verma A, Khandelwal N, Nagori H, Singh N, et al. Resistance evolution against host-directed antiviral agents: buffalopox virus switches to use p38-upsilon under long-term selective pressure of an inhibitor targeting p38-alpha. Mol Biol Evol. 2022;39:msac177.","journal-title":"Mol Biol Evol"},{"key":"6735_CR41","doi-asserted-by":"crossref","unstructured":"Pucci G, Minafra L, Bravata V, Calvaruso M, Turturici G, Cammarata FP, et al. Glut-3 gene knockdown as a potential strategy to overcome glioblastoma radioresistance. Int J Mol Sci. 2024;25:2079.","DOI":"10.3390\/ijms25042079"},{"key":"6735_CR42","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1111\/cns.13892","volume":"28","author":"Y Liu","year":"2022","unstructured":"Liu Y, Shi Y, Wu M, Liu J, Wu H, Xu C, et al. Hypoxia-induced polypoid giant cancer cells in glioma promote the transformation of tumor-associated macrophages to a tumor-supportive phenotype. CNS Neurosci Ther. 2022;28:1326\u201338.","journal-title":"CNS Neurosci Ther"},{"key":"6735_CR43","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.stemcr.2015.03.005","volume":"4","author":"P Cheng","year":"2015","unstructured":"Cheng P, Phillips E, Kim SH, Taylor D, Hielscher T, Puccio L, et al. Kinome-wide shRNA screen identifies the receptor tyrosine kinase AXL as a key regulator for mesenchymal glioblastoma stem-like cells. Stem Cell Rep. 2015;4:899\u2013913.","journal-title":"Stem Cell Rep"},{"key":"6735_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-023-03073-x","volume":"24","author":"MYY Lee","year":"2023","unstructured":"Lee MYY, Kaestner KH, Li M. Benchmarking algorithms for joint integration of unpaired and paired single-cell RNA-seq and ATAC-seq data. Genome Biol. 2023;24:244.","journal-title":"Genome Biol"},{"key":"6735_CR45","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.str.2020.06.006","volume":"28","author":"IT Desta","year":"2020","unstructured":"Desta IT, Porter KA, Xia B, Kozakov D, Vajda S. Performance and its limits in rigid body protein-protein docking. Structure. 2020;28:1071\u2013-81. e3","journal-title":"Structure"},{"key":"6735_CR46","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/nrclinonc.2016.204","volume":"14","author":"G Reifenberger","year":"2017","unstructured":"Reifenberger G, Wirsching HG, Knobbe-Thomsen CB, Weller M. Advances in the molecular genetics of gliomas - implications for classification and therapy. Nat Rev Clin Oncol. 2017;14:434\u201352.","journal-title":"Nat Rev Clin Oncol"},{"key":"6735_CR47","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987\u201396.","journal-title":"N Engl J Med"},{"key":"6735_CR48","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3322\/caac.20069","volume":"60","author":"EG Van Meir","year":"2010","unstructured":"Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, Olson JJ. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin. 2010;60:166\u201393.","journal-title":"CA Cancer J Clin"},{"key":"6735_CR49","first-page":"58","volume":"10","author":"A Prelaj","year":"2019","unstructured":"Prelaj A, Rebuzzi SE, Grassi M, Salvati M, D\u2019Elia A, Buttarelli F, et al. Non-conventional fotemustine schedule as second-line treatment in recurrent malignant gliomas: survival across disease and treatment subgroup analysis and review of the literature. Mol Clin Oncol. 2019;10:58\u201366.","journal-title":"Mol Clin Oncol"},{"key":"6735_CR50","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1124\/pr.117.014944","volume":"70","author":"A Shergalis","year":"2018","unstructured":"Shergalis A, Bankhead A 3rd, Luesakul U, Muangsin N, Neamati N. Current challenges and opportunities in treating glioblastoma. Pharmacol Rev. 2018;70:412\u201345.","journal-title":"Pharmacol Rev"},{"key":"6735_CR51","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.semcancer.2020.09.011","volume":"80","author":"Z Ma","year":"2022","unstructured":"Ma Z, Xiang X, Li S, Xie P, Gong Q, Goh BC, et al. Targeting hypoxia-inducible factor-1, for cancer treatment: recent advances in developing small-molecule inhibitors from natural compounds. Semin Cancer Biol. 2022;80:379\u201390.","journal-title":"Semin Cancer Biol"},{"key":"6735_CR52","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13045-022-01292-6","volume":"15","author":"Q Wu","year":"2022","unstructured":"Wu Q, You L, Nepovimova E, Heger Z, Wu W, Kuca K, et al. Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape. J Hematol Oncol. 2022;15:77.","journal-title":"J Hematol Oncol"},{"key":"6735_CR53","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13046-020-01820-7","volume":"40","author":"B Wang","year":"2021","unstructured":"Wang B, Zhao Q, Zhang Y, Liu Z, Zheng Z, Liu S, et al. Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy. J Exp Clin Cancer Res. 2021;40:24.","journal-title":"J Exp Clin Cancer Res"},{"key":"6735_CR54","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1159\/000354487","volume":"32","author":"M Wolff","year":"2013","unstructured":"Wolff M, Jelkmann W, Dunst J, Depping R. The aryl hydrocarbon receptor nuclear translocator (ARNT\/HIF-1beta) is influenced by hypoxia and hypoxia-mimetics. Cell Physiol Biochem. 2013;32:849\u201358.","journal-title":"Cell Physiol Biochem"},{"key":"6735_CR55","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.00503-21","volume":"42","author":"AM Cooper","year":"2022","unstructured":"Cooper AM, Nutter CA, Kuyumcu-Martinez MN, Wright CW. Alternative splicing of the aryl hydrocarbon receptor nuclear translocator (ARNT) is regulated by RBFOX2 in lymphoid malignancies. Mol Cell Biol. 2022;42:e0050321.","journal-title":"Mol Cell Biol"},{"key":"6735_CR56","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.3390\/cells11182811","volume":"11","author":"M Zhang","year":"2022","unstructured":"Zhang M, Zhang Y, Ding Y, Huang J, Yao J, Xie Z, et al. Regulating the expression of HIF-1alpha or lncRNA: potential directions for cancer therapy. Cells. 2022;11:2811.","journal-title":"Cells"},{"key":"6735_CR57","doi-asserted-by":"publisher","first-page":"6102","DOI":"10.3390\/ijms21176102","volume":"21","author":"G Maik-Rachline","year":"2020","unstructured":"Maik-Rachline G, Lifshits L, Seger R. Nuclear P38: roles in physiological and pathological processes and regulation of nuclear translocation. Int J Mol Sci. 2020;21:6102.","journal-title":"Int J Mol Sci"},{"key":"6735_CR58","doi-asserted-by":"publisher","first-page":"46707","DOI":"10.1074\/jbc.M106176200","volume":"276","author":"NA Bhowmick","year":"2001","unstructured":"Bhowmick NA, Zent R, Ghiassi M, McDonnell M, Moses HL. Integrin beta 1 signaling is necessary for transforming growth factor-beta activation of p38MAPK and epithelial plasticity. J Biol Chem. 2001;276:46707\u201313.","journal-title":"J Biol Chem"},{"key":"6735_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2794","volume":"12","author":"L Mao","year":"2010","unstructured":"Mao L, Yuan L, Slakey LM, Jones FE, Burow ME, Hill SM. Inhibition of breast cancer cell invasion by melatonin is mediated through regulation of the p38 mitogen-activated protein kinase signaling pathway. Breast Cancer Res. 2010;12:R107.","journal-title":"Breast Cancer Res"},{"key":"6735_CR60","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1038\/sj.onc.1201380","volume":"15","author":"S Rousseau","year":"1997","unstructured":"Rousseau S, Houle F, Landry J, Huot J. p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells. Oncogene. 1997;15:2169\u201377.","journal-title":"Oncogene"},{"key":"6735_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e21771","volume":"9","author":"M Xun","year":"2023","unstructured":"Xun M, Wang J, Xie Q, Peng B, Li Z, Guo Z, et al. FBXL19 promotes malignant behaviours by activating MAPK signalling and negatively correlates with prognosis in hepatocellular carcinoma. Heliyon. 2023;9:e21771.","journal-title":"Heliyon"},{"key":"6735_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.975197","volume":"13","author":"N Grave","year":"2022","unstructured":"Grave N, Scheffel TB, Cruz FF, Rockenbach L, Goettert MI, Laufer S, et al. The functional role of p38 MAPK pathway in malignant brain tumors. Front Pharmacol. 2022;13:975197.","journal-title":"Front Pharmacol"},{"key":"6735_CR63","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1096\/fj.02-0329fje","volume":"17","author":"K Issbrucker","year":"2003","unstructured":"Issbrucker K, Marti HH, Hippenstiel S, Springmann G, Voswinckel R, Gaumann A, et al. p38 MAP kinase-a molecular switch between VEGF-induced angiogenesis and vascular hyperpermeability. FASEB J. 2003;17:262\u20134.","journal-title":"FASEB J"},{"key":"6735_CR64","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1126\/science.1852076","volume":"252","author":"EC Hoffman","year":"1991","unstructured":"Hoffman EC, Reyes H, Chu FF, Sander F, Conley LH, Brooks BA, et al. Cloning of a factor required for activity of the Ah (dioxin) receptor. Science. 1991;252:954\u20138.","journal-title":"Science"},{"key":"6735_CR65","doi-asserted-by":"publisher","first-page":"5510","DOI":"10.1073\/pnas.92.12.5510","volume":"92","author":"GL Wang","year":"1995","unstructured":"Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA. 1995;92:5510\u20134.","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-024-06735-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-024-06735-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-024-06735-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T15:02:12Z","timestamp":1716908532000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-024-06735-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,28]]},"references-count":65,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5]]}},"alternative-id":["6735"],"URL":"https:\/\/doi.org\/10.1038\/s41419-024-06735-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3839308\/v1","asserted-by":"object"}]},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,28]]},"assertion":[{"value":"6 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Scientific Ethics Committee at the Guangdong Provincial People\u2019s Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All the patients\u2019 samples used in this study have obtained necessary consent. Consent for publication was obtained from the participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"366"}}